Engflag

Inzee

Quick links to important sections

Inzee

Inzee_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Inzee

Property Description
Active Ingredient Loratadine
Form Tablet, Syrup, Capsule, Solution (Oral)
Pharmacological Class Second-generation Antihistamine
General Purpose Relieves general allergy symptoms
Origin Synthetic, Piperidine derivative

What Type of Medicine Is Inzee (Loratadine)?

Inzee is a synthetic, single-ingredient drug classified as a second-generation tricyclic antihistamine medication. The core of the medicine is the active ingredient Loratadine, which is a piperidine derivative compound. This anti-allergic agent is clinically recognized for managing symptoms resulting from the body's hypersensitivity reactions. The distinction of being a second-generation agent is a primary differentiating factor in its profile; this class exhibits peripheral selectivity, unlike older compounds, leading to its typically non-sedating profile.

Composition and Forms of Loratadine

The entire function of Inzee is based on the action of Loratadine, which is the sole chemically active component in the preparation. The active substance is combined with a basic pharmaceutical base to create different pharmaceutical preparations, all intended for oral administration. The various dosage forms include the traditional tablet and the liquid syrup or solution, alongside options like the capsule or rapidly-disintegrating tablet. This range of presentations provides administrative flexibility; for example, the syrup form facilitates easier intake for certain patient groups.

How Does Inzee Generally Relieve Allergy Symptoms?

Inzee functions by acting as a selective peripheral histamine H₁-receptor antagonist, blocking the effects of the chemical histamine which the body releases during an allergic episode. The drug is indicated for the general relief of common symptoms associated with allergies. This action provides targeted relief for typical scenarios like seasonal changes causing a runny nose, sneezing, or itchy, watery eyes. Loratadine is a compound with a sustained long-acting effect and minimal impact on cognitive function. This supports the medication’s role in providing relief from general allergy symptoms without causing the daily impairment often associated with older compounds.

Regulatory References

  1. NIH MedlinePlus Loratadine

What side effects are possible with Inzee?

Possible Side Effects and Safety Information for Inzee

Adverse reactions associated with Inzee are documented in regulatory labeling based on data collected from clinical trials and post-marketing surveillance. This information is categorized using standard medical terminology (System Organ Classes) and classified by frequency, typically according to the ICH/CIOMS framework (e.g., Very Common, Common, Uncommon, Rare).

Serious and Clinically Significant Reactions

The prescribing information highlights specific serious adverse reactions that require immediate attention. These are defined as events that may result in death, be life-threatening, or require hospitalization. Safety documents also include warnings for clinically significant adverse reactions that, though not classified as serious, represent important risks. These may involve effects on major body systems, such as the cardiovascular, nervous, or gastrointestinal systems, and are subject to continuous post-marketing monitoring.

Safety Restrictions and Special Populations

  • Contraindications and Restrictions: The official label specifies patient populations or pre-existing conditions where Inzee is strictly contraindicated due to an unacceptably high risk. Additionally, formal warnings or limitations of use may be present, identifying situations that require particular caution or specific monitoring before and during therapy.
  • Population Considerations: Specific safety data are often delineated for subpopulations, including pediatric and geriatric patients, as well as individuals with severe renal or hepatic impairment, where exposure or risk profiles may differ from the general adult population. In some cases, a dose-relationship for certain adverse events has been explicitly identified through regulatory analysis.

Monitoring Notes

The label indicates high-level monitoring requirements, such as the need for periodic laboratory testing or vital sign checks, which are necessary to manage identified risks related to the drug's safety profile.

Overdose and Emergency Response

The official regulatory documentation for Inzee (Loratadine) establishes specific clinical manifestations associated with overdosage and mandates immediate emergency action.

Documented Manifestations and Risks

The most frequently reported manifestations following the ingestion of a dose greater than recommended include central nervous system effects such as somnolence (drowsiness) and headache. Cardiovascular findings, specifically tachycardia (fast heart rate), are also reported in regulatory documentation. Overdosage is further associated with an increased occurrence of anticholinergic symptoms. While management addresses these manifestations, potential severe outcomes like cardiac arrhythmias and prolongation of the QT-interval are documented risks in cases of massive ingestion. Population-specific regulatory notes indicate that overdose symptoms may be more pronounced or severe in children and older adults.

Mandated Emergency Response and Management

Official government guidelines require individuals to seek immediate medical help or contact a Poison Control Center right away when an overdose is suspected. This action is mandated even if pronounced symptoms are not yet evident. The official management strategy is defined as strictly symptomatic and supportive, as no specific antidote is known for Loratadine. Procedural measures that may be considered include the administration of activated charcoal or gastric lavage. Furthermore, regulatory documents state that continued medical monitoring of the patient is required following emergency treatment, with cardiac monitoring potentially necessary in significant overdosage scenarios.

Therapeutic Uses of Inzee

What Inzee Treats: Main Uses and Benefits

The medication is commonly used to help with symptoms related to physical discomfort caused by allergic hypersensitivity. Inzee may be part of symptomatic management across conditions presenting with episodic or fluctuating symptom patterns driven by common allergens. It is relevant for easing symptom clusters associated with allergic rhinitis (hay fever), certain chronic skin manifestations, and accompanying ocular irritation.

Symptom Domains and Therapeutic Benefits

Inzee is commonly used to help manage symptom clusters that may become intense or disruptive, such as sneezing, profuse runny nose (rhinorrhea), itching/watering eyes, and generalized pruritus (skin itching) that characterize allergic episodes. The medication is applied in clinical settings where supportive symptom management is appropriate for recurrent or chronic manifestations. This support can contribute to improved comfort during periods of heightened symptoms and assists with maintaining functional stability during active hours.

“Inzee is generally considered relevant for easing distress and provides supportive relief that helps patients cope more steadily with symptom fluctuations.”

Quick Fact: Symptomatic Support for Nasal Discharge Inzee may be applied during phases when symptoms intensify and supportive relief is needed; it can assist with managing the nasal discharge and sneezing that create noticeable functional strain.

Common Indications (Brief Listing)

The medication is considered relevant for easing symptoms associated with conditions involving episodic or fluctuating manifestations, such as seasonal allergic rhinitis, perennial rhinitis, and certain allergic dermatologic conditions.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility for Inzee (Loratadine): Official Regulatory Status

Official regulatory documents define the eligible population for Inzee (Loratadine) based on age, physiological status, and the presence of certain medical conditions or known allergies.

Populations for Whom Use is Allowed

Age Group Eligibility Status (Regulatory Wording)
Adults and Adolescents Approved for use in individuals aged 12 years and older.
Children Approved for use in children aged 2 years and older.

Absolute Contraindications

Use is contraindicated and absolutely prohibited for the following groups:

  • Hypersensitivity: Individuals with a known allergy or documented hypersensitivity to loratadine or any excipients in the specific formulation.
  • Children Under 2 Years: Safety and efficacy have not been established in this age group.
  • Metabolic Conditions: Patients with certain hereditary sugar malabsorption disorders (e.g., galactose intolerance, Lapp lactase deficiency) must not use tablet forms containing lactose. For formulations containing phenylalanine (aspartame), patients with Phenylketonuria (PKU) are excluded.

Restricted or Conditional Use

Specific populations require conditional use, as the drug's clearance may be affected:

  • Severe Liver Impairment: Patients with severe hepatic disease may require a lower initial dose, such as 10 mg every other day, as stated by some regulators.
  • Severe Renal Impairment: Individuals with severe kidney disease (GFR < 30 mL/min) may also require a modified dose due to altered drug concentrations.

Pregnancy and Lactation Eligibility

The medicine is generally not recommended for women who are pregnant (as a precautionary measure) or who are breastfeeding (because the substance is known to be excreted in breast milk). Regulatory documents advise against use in these populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Loratadine (Inzee) as defined by governmental regulatory authorities.

Pharmacokinetic Drug-Drug Interactions

Co-administration with specific inhibitors of cytochrome P450 enzymes—namely CYP3A4 and CYP2D6—is formally documented to alter Loratadine's systemic exposure. Medicines explicitly listed in regulatory labeling that cause this effect include Ketoconazole, Erythromycin, and Cimetidine. The pharmacokinetic interaction with these agents results in substantially increased plasma concentrations (AUC and Cmax) of Loratadine.

Regulatory data confirms, however, that while plasma levels increase, clinical trials have not identified clinically significant changes in the safety profile, including cardiac measurements.

Food and Substance Interactions

The presence of food is documented to have a pharmacokinetic effect, increasing the systemic bioavailability of Loratadine by approximately 40% and delaying the time to peak concentration (Tmax).

Official psychomotor performance studies have shown that Loratadine has no potentiating effects when administered concomitantly with alcohol.

Administration-Timing Restrictions

Administration of Loratadine must be discontinued at least 48 hours before carrying out allergy skin tests (dermal reactivity index). This mandatory separation period is required because antihistamines may prevent or reduce the development of positive test results.

Population-Specific Interaction Notes

Patients with severe hepatic impairment are subject to reduced clearance of Loratadine. This condition-specific interaction leads to an approximate doubling of the systemic exposure (AUC and Cmax) of Loratadine and its active metabolite.

Mechanism of Action

Modulation of Receptor-Mediated Signaling

Inzee works by engaging specific cell-surface receptors, initiating a cascade that either suppresses or enhances downstream signaling. This action targets pathways characterized by overactive or dysregulated processes, modifying the balance of activity within target biological systems.

Fine-Tuning Key Pathway Cascades

The drug modifies early molecular steps within critical pathways, which influences the systemic physiological outcomes associated with heightened responses. The influence on these mechanistic cascades affects feedback regulation and adjustments that result in an altered physiological state.

Modulation of Physiological Activity

Inzee's mechanism modulates activity by altering the output or influence of mediators within target systems. This action results in physiological adjustments that alter the profile of processes driven by distinct, often accelerated, signaling patterns.

Dosage and Administration Information

Instruction Map: How to use Inzee (Loratadine) — Administration Guidelines

The administration guidelines for Loratadine define the specific route, dose, and frequency for its correct use.

Feature Instruction
Route of Administration Oral.
Dosing Schedule Adults/ ge 6 years: 10 mg once daily. Children 2–5 years: 5 mg once daily. The total daily dose must not exceed 10 mg.
Timing in relation to meals May be taken with or without food.
Preparation Requirements Liquid solutions (syrup) require accurate measurement using the enclosed calibrated device. Rapidly-disintegrating tablets are placed on the tongue to dissolve and do not require water.
Age-Group Administration Rules Dosing is standardized by age or weight, with children over 6 years receiving the standard adult dose.
Missed-Dose Rules If a dose is forgotten, it may be taken as soon as it is remembered. If it is almost time for the next scheduled dose, the missed dose should be skipped to prevent taking a double amount.
Special Procedural Conditions For patients with severe hepatic impairment, the recommended dosing is reduced to 10 mg every other day. Administration must be suspended for a minimum of 48 hours prior to any diagnostic allergy skin testing.

Instruction Classifications (High-Level)

  • Administration method type: Oral.
  • Frequency pattern: Once daily (qDay) under normal circumstances.
  • Instructional basis: Standardized pharmacological guidelines.
  • Use-context constraints: Dosage adjustment in frequency is required for severe organ impairment; temporary cessation is mandated before skin testing.

Connection to the overall use protocol

The instructions establish a fixed, once-daily oral administration protocol designed for use across various labeled dosage forms. The key procedural variable is a required adjustment in the dosing frequency for individuals with severe hepatic or renal impairment, defining a specific, reduced regimen for these patient groups. The overall use pattern is defined by the 24-hour frequency with an absolute daily dose limit.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Inzee (Loratadine)

Evidence for Use in Allergic Rhinitis

The evidence foundation for research exploring Loratadine in the context of allergic rhinitis—which includes both seasonal (hay fever) and perennial (year-round) forms—was evaluated in numerous studies. Researchers have primarily used short-term Randomized Controlled Trials (RCTs), a key type of study for clinical evaluation, to evaluate the medicine. These studies examined outcomes related to physical discomfort, such as changes in sneezing, runny nose, nasal itching, and watery eyes. The research explored how symptoms change over time and typically included both adults and adolescents.

Across numerous studies, including large meta-analyses, the evidence includes data showing measurements related to symptom severity scores compared to an inactive substance (placebo). Comparative trials were also conducted, where Loratadine was evaluated in relation to other H1-antihistamines, and used to measure differences in specific outcomes, such as the reported onset and duration of action. The findings from these trials provide context on symptom patterns observed during short periods of use.

Evidence for Use in Chronic Urticaria

The primary research consists of short-term to intermediate-term RCTs that examined outcomes related to physical discomfort in patients with chronic urticaria (hives/skin itching). These studies focused specifically on the severity of generalized pruritus (skin itching) and the number and size of wheals (hives). In trials, Loratadine was observed in research scenarios to show patterns of symptom score changes compared to placebo when evaluated over study periods that were typically 2 to 4 weeks in length.

Research on Follow-up Duration and Uncertainty

The bulk of the clinical evaluation relies on short-term studies, and the follow-up durations were limited for fully understanding the maintenance of the effect over years. The evidence so far indicates that the observed patterns of change in symptoms during the short study windows may be consistent. However, the available data does not determine whether an individual will respond similarly after using the medicine continuously for extended periods. For specific groups, such as children down to 2 years of age or individuals with liver/kidney problems, data for certain groups remain insufficient from dedicated clinical studies, and results apply only to the populations studied in the primary RCTs.

Key Studies & References

  1. Nonsedating H1 antihistamines in the treatment of chronic urticaria. A large, multicenter, double-blind, placebo-controlled clinical trial

Frequently Asked Questions (FAQ)

Common questions about Inzee (FAQ)

Q: Is Inzee available over the counter?

A: The active ingredient in Inzee, Loratadine, has been approved for non-prescription use and is widely available as an Over-The-Counter (OTC) medicine. This regulatory status allows it to be purchased without the need for a prescription in many countries.

Q: What is the regulatory status of Inzee in terms of its approval date?

A: Loratadine was originally approved by the United States Food and Drug Administration (FDA) as a prescription medicine in 1993. Its regulatory status was later switched, and it was approved for Over-The-Counter (OTC) use in 2002.

Q: Is there a generic version of Inzee available?

A: Yes, the active ingredient Loratadine is off-patent and is widely available as a generic medication. The availability of generic alternatives is a common result of a drug’s regulatory history.

Q: Is Inzee a narcotic or controlled substance?

A: Loratadine is not classified as a narcotic or a controlled substance by the U.S. Drug Enforcement Administration. Official records indicate that it is designated with a DEA Schedule of None.

Q: Is Inzee approved in countries outside the US?

A: Yes, Loratadine is approved and available for use in many countries globally. It is recognized and regulated by major governmental bodies, including those in Europe, Canada, and Australia.

Q: Why does Inzee have a boxed warning (Black Box Warning)?

A: The official FDA prescribing information for Loratadine, the active ingredient in Inzee, does not contain a Black Box Warning. This is the most stringent safety warning issued by the FDA.

Q: How quickly does Inzee start working?

A: Studies of Loratadine, the active ingredient in Inzee, suggest that the onset of action for allergy symptom relief can be observed approximately 75 minutes after it is taken. This indicates how quickly the medicine begins to work in the body.

Q: How long does the effect of Inzee last?

A: Official product information confirms that Inzee is a long-acting antihistamine. It is intended to be taken once daily to provide continuous relief of allergy symptoms for up to 24 hours.

Q: What is the difference between the starting use and the maintenance use of Inzee?

A: The official instructions specify a single standard dose (e.g., once daily) for use in normal adult populations. This same regimen is specified for both the initial use and the ongoing maintenance phase of treatment.

Q: Is Inzee used for other conditions besides the main one it treats?

A: The medicine is approved to treat symptoms associated with two main conditions: seasonal and perennial allergic rhinitis (hay fever) and chronic spontaneous urticaria (hives and allergic skin rash).

Q: What is the official definition of the condition Inzee is designed to treat?

A: Inzee is indicated for the relief of the typical symptoms associated with allergic rhinitis, such as sneezing and runny nose, and for relieving the itching related to chronic spontaneous urticaria (hives/allergic skin rash).

Q: How is Inzee different from the older drug that treats the same condition?

A: Inzee is classified as a second-generation antihistamine, which makes it distinct from older agents. This class is designed to be typically non-sedating because the active ingredient does not readily cross the protective blood-brain barrier.

Q: What organs does Inzee affect, according to the official documents?

A: Official documents describe that the drug is primarily metabolized by the liver, and the medicine and its metabolites are eliminated from the body by the kidneys and in the feces. The drug's therapeutic action affects receptors located in various body systems, including the respiratory tract and blood vessels.

Q: Are there common side effects that people notice with Inzee?

A: According to regulatory data from clinical trials, the most commonly reported side effects include headache, feelings of tiredness (fatigue), dry mouth, and some instances of sleepiness. These common effects were generally mild.

Q: What are the most serious side effects listed for Inzee?

A: Official warnings highlight the risk of severe allergic reactions, known as anaphylaxis, as a potentially serious risk. These reactions may involve hives along with trouble swallowing, swelling of the face or tongue, or difficulty breathing.

Q: Are headaches a frequent side effect of Inzee?

A: Yes, regulatory data indicates that headache is one of the most frequently reported side effects associated with Loratadine use during clinical studies.

Q: Can Inzee cause dry mouth?

A: Yes, dry mouth is listed in the regulatory documents as one of the commonly reported side effects associated with Loratadine use.

Q: Is Inzee known to cause any skin reactions or rashes?

A: Yes, regulatory information states that a skin rash and the development of hives (urticaria) are potential signs of an allergic reaction to the product or its components.

Q: Is Inzee known to cause changes in mood or sleep?

A: Clinical information indicates that sleepiness or drowsiness is a reported side effect of the medicine. The regulatory label does not specifically mention changes in mood.

Q: What if I experience mild dizziness after using Inzee?

A: Dizziness is listed as a less commonly reported side effect. The patient label includes warnings stating that if this dizziness is severe or occurs alongside other signs of a serious allergic reaction, medical attention should be sought immediately.

Q: What should I do if I notice a side effect not listed in the patient information?

A: Regulatory authorities, such as the FDA, encourage patients and healthcare professionals to report any adverse events or side effects not listed in the official patient information to help ensure ongoing drug safety monitoring.

Q: Does Inzee make you feel tired or drowsy?

A: The medicine is generally classified as non-drowsy when used as directed. However, regulatory data indicates that sleepiness or drowsiness was reported in a small percentage of individuals during clinical trials.

Q: What does the patient leaflet say about allergic reactions to Inzee?

A: The patient information warns that signs of a severe allergic reaction may include sudden hives, swelling of the face or tongue, or difficulty breathing. The label carries a warning that if these symptoms are noticed, immediate medical attention should be sought.

Q: Is Inzee safe for elderly people to use?

A: Second-generation antihistamines like Inzee are generally considered appropriate for use in the elderly population. Regulatory reviews note that older individuals may have variability in how their bodies process the medicine.

Q: Why do official sources list a certain group of people who should not use Inzee?

A: Official documents list contraindications to prevent known safety risks, such as a severe allergic reaction to the ingredients. Restrictions are also in place for individuals with severe liver or kidney disease where the body’s ability to clear the medicine is reduced.

Q: How long can a person safely use Inzee?

A: The over-the-counter labeling indicates that the medicine is used for the temporary relief of symptoms. Official guidance states that a healthcare professional should be consulted if allergy symptoms do not improve after a period of three to seven days of use.

Q: Do I need a follow-up appointment after starting Inzee?

A: The patient label does not mandate a routine follow-up appointment for most users. However, the label includes guidance stating that a healthcare professional should be consulted if allergy symptoms persist or do not improve after starting the medicine.

Q: Can I use Inzee if I have high blood pressure?

A: The official labeling for the single-ingredient product does not list high blood pressure as a contraindication. However, certain combination products that pair Loratadine with a decongestant carry a warning about consulting a healthcare professional before use if high blood pressure is present.

Q: Can I take Inzee if I'm also taking a vitamin supplement?

A: The official label includes general advice regarding informing a healthcare professional about all the products taken. This applies to any vitamins, herbal products, or supplements being used.

Q: Is it okay to drink coffee while taking Inzee?

A: There is no specific drug interaction documented between the single-ingredient product Loratadine and coffee. For combination products that include a decongestant, using the medicine with excessive caffeine intake may increase the risk of side effects.

Q: Can Inzee interfere with birth control pills?

A: Drug interaction analyses indicate that there is no known interaction documented between Loratadine and common hormonal birth control pills.

Q: What happens if I accidentally use more Inzee than described in the instructions?

A: Official warnings state that in case of accidental overuse or overdose, the warning is to contact a Poison Control Center or seek medical help immediately. Symptoms may include a fast heartbeat or extreme sleepiness.

How should Inzee be stored and disposed of?

Storage and Environmental Control

Official labeling mandates that Inzee (Loratadine) tablets and oral solution be stored at controlled room temperature, typically defined as 20 C to 25 C (68 F to 77 F). The product must be stored out of the reach and sight of children and protected from light and moisture. All formulations must be kept in their original container; liquid forms must be tightly closed to maintain product integrity, and the medicine must not be frozen.

Disposal Requirements

Unused or expired Inzee product must be disposed of in accordance with local requirements for pharmaceutical waste. The recommended method for most unused medicines is through an official drug take-back program. If a take-back option is unavailable, the U.S. FDA recommends discarding the medicine in the household trash after mixing it with an unpalatable substance and sealing it in a container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Inzee found in:

A-Z Index: